Skip Navigation


European Heart Journal Advance Access originally published online on August 8, 2005
European Heart Journal 2005 26(18):1818-1819; doi:10.1093/eurheartj/ehi309
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
26/18/1818    most recent
ehi309v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Related articles in EHJ
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (2)
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Amarenco, P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Amarenco, P.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The European Society of Cardiology 2005. All rights reserved. For Permissions, please e-mail: journals.permissions@oupjournals.org

Lipid lowering and recurrent stroke: another stroke paradox?

Pierre Amarenco*

Department of Neurology and Stroke Centre, Bichat Hospital and Medical School, Denis Diderot University, Paris, France

* Corresponding author. Tel: +33 1 4025 8725; fax: +33 1 4025 7198. E-mail address: pierre.amarenco@bch.ap-hop-paris.fr

This editorial refers to ‘Plasma lipids predict myocardial infarction, but not stroke, in patients with established cerebrovascular disease’{dagger} by A. Patel et al., on page 1910

The first 10% of the full text of this article appears below.

The meta-analysis of over 90 000 patients included in statin tria ls shows a significant 21% reduction of stroke with no heterogeneity between trials and no increase in haemorrhagic stroke.1 Because the link between total cholesterol and incident stroke has never been clearly established in epidemiological studies,2 it is surprising to see, in the meta-analysis, that the larger the between-group LDL level difference the greater the stroke risk reduction.1 Indeed, we calculated that LDL reduction could explain 35–80% of the benefit of statins on stroke risk reduction, leaving room for other non-lipid lowering effects of statins, the so-called pleiotropic effects, but the main effect is through LDL reduction.1 New results from randomized trials since this meta-analysis, have confirmed that LDL lowering . . . [Full Text of this Article]

Blood cholesterol and recurrent stroke, another paradox?

Blood cholesterol lowering and recurrent stroke, is this effective?

Is there a true stroke paradox?

Cholesterol and stroke: the jury is still out


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?

Related articles in EHJ:

Plasma lipids predict myocardial infarction, but not stroke, in patients with established cerebrovascular disease
Anushka Patel, Mark Woodward, Duncan J. Campbell, David R. Sullivan, Samuel Colman, John Chalmers, Bruce Neal, and Stephen MacMahon
EHJ 2005 26: 1910-1915. [Abstract] [Full Text]